
|Articles|July 1, 2017
Adverse Reactions Associated with Biologics for Moderate-to-Severe Plaque Psoriasis
In July, our table of the month sums up biologics approved for moderate-to-severe plaque psoriasis and common adverse events associated with these biologics.
Advertisement
Links to PDF
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















